Idiopathic Interstitial Pneumonia
8
0
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Japanese Idiopathic Interstitial Pneumonias Registry
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
The Relationship Between Hormone Sensitivity and Imaging of Idiopathic Interstitial Pneumonia by Artificial Intelligence
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)
Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-up
Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease